ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)
Upcoming Articles
Explore Our New Articles
Trending
Latest News
Urine C-reactive protein content and non-invasive molecular grading of renal cell carcinoma
Introduction
Renal cell carcinoma (RCC) accounts for 4.2% of adult malignancies and is the 10th leading cause of cancer deaths in the United States.1 In the United States in 2024, more than 81,000 new cases were diagnosed and more than 14,300 died, due…
Practice-Ready Molecular Imaging in Renal Cell Carcinoma
Abstract :
BACKGROUND: Renal cell carcinoma (RCC) is the most common kidney malignancy, often associated with poor prognosis due to late-stage diagnosis and metastasis. Recent research has identified PIWI-interacting RNAs (piRNAs) and PIWI-like proteins as potential biomarkers and therapeutic targets in cancer,…
The New Frontier: Advancements in Kidney Cancer Treatment
Thomas E. Hutson, DO, PharmD
Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415
Correspondence to: Thomas Hutson, DO, PharmD
Dear colleagues,
The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. As editors,…
Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157.
Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…
The Future of RCC Treatment
Thomas E. Hutson, DO, PharmD
Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD
The Kidney Cancer Journal is pleased to receive and review the expert consensus manuscript stemming from the IKCSEU24 Think…
Current Trends
Thomas E. Hutson, DO, PharmD
Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD
The Kidney Cancer Journal is pleased to receive and review the expert consensus manuscript stemming from the IKCSEU24 Think…
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157.
Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…
Thomas E. Hutson, DO, PharmD
Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415
Correspondence to: Thomas Hutson, DO, PharmD
Dear colleagues,
The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. As editors,…
